Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
UTHR [NASD]
United Therapeutics Corporation
Index- P/E29.39 EPS (ttm)3.27 Insider Own0.10% Shs Outstand50.48M Perf Week1.80%
Market Cap4.85B Forward P/E11.50 EPS next Y8.36 Insider Trans-75.67% Shs Float49.70M Perf Month0.27%
Income174.60M PEG3.92 EPS next Q1.65 Inst Own96.90% Short Float13.50% Perf Quarter-13.30%
Sales1.12B P/S4.34 EPS this Y-42.60% Inst Trans-0.05% Short Ratio7.96 Perf Half Y17.35%
Book/sh25.94 P/B3.71 EPS next Y20.83% ROA9.30% Target Price106.00 Perf Year57.35%
Cash/sh13.64 P/C7.05 EPS next 5Y7.50% ROE14.00% 52W Range59.05 - 116.65 Perf YTD-15.01%
Dividend- P/FCF12.33 EPS past 5Y38.20% ROI11.80% 52W High-17.61% Beta1.43
Dividend %- Quick Ratio1.30 Sales past 5Y31.70% Gross Margin88.30% 52W Low62.76% ATR4.19
Employees706 Current Ratio1.30 Sales Q/Q18.50% Oper. Margin26.20% RSI (14)50.87 Volatility4.59% 4.60%
OptionableYes Debt/Eq0.22 EPS Q/Q-136.40% Profit Margin15.60% Rel Volume1.79 Prev Close94.77
ShortableYes LT Debt/Eq0.00 EarningsApr 21 Payout0.00% Avg Volume842.90K Price96.11
Recom2.40 SMA201.44% SMA50-1.62% SMA2008.59% Volume1,476,200 Change1.41%
07-Apr-14Upgrade Standpoint Research Hold → Buy $118
26-Feb-14Reiterated RBC Capital Mkts Sector Perform $80 → $90
26-Feb-14Reiterated Ladenburg Thalmann Buy $138 → $135
31-Dec-13Reiterated Argus Buy $120 → $130
23-Dec-13Upgrade Ladenburg Thalmann Neutral → Buy $138
02-Dec-13Reiterated Argus Buy $85 → $110
05-Aug-13Reiterated Argus Buy $75 → $85
30-Jul-13Downgrade Standpoint Research Buy → Hold
20-Jun-13Upgrade Standpoint Research Hold → Buy
15-May-13Downgrade Standpoint Research Buy → Hold
25-Mar-13Reiterated Ladenburg Thalmann Buy $69 → $63
27-Feb-13Reiterated RBC Capital Mkts Sector Perform $45 → $50
03-Aug-12Downgrade Standpoint Research Buy → Hold
27-Apr-12Downgrade Canaccord Genuity Buy → Hold
26-Mar-12Initiated Canaccord Genuity Buy $56
12-Mar-12Initiated Standpoint Research Buy $65
14-Feb-12Reiterated Brean Murray Buy $55 → $57
25-Aug-11Reiterated Oppenheimer Outperform $77 → $53
25-Aug-11Downgrade Maxim Group Buy → Hold
25-Aug-11Downgrade Auriga Hold → Sell $90 → $45
07-Apr-14 11:16AM  United Therapeutics upgraded by Standpoint Research Briefing.com
01-Apr-14 04:03AM  United Therapeutics: 7 Different Insiders Have Sold Shares This Month at Seeking Alpha
26-Mar-14 05:33PM  [video] The false temptation of growth at CNBC
09:13AM  Todays Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam at Motley Fool
06:00AM  Japan's Ministry of Health, Labour and Welfare Grants Approval for United Therapeutics' Remodulin PR Newswire
18-Mar-14 04:31PM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
16-Mar-14 05:16PM  Supernus Pharmaceuticals: 2013 Revenues Exceed Analyst & Company Expectations; Maintaining Positive Outlook at Seeking Alpha
11-Mar-14 01:56PM  United Therapeutics retreats after FDA denies petition on Remodulin label at theflyonthewall.com
01:56PM  United Therapeutics retreats after FDA denies petition on Remodulin label
12:52PM  United Therapeutics: A Profitable Biotech With A Potentially Undervalued Pipeline at Seeking Alpha
12:52PM  United Therapeutics: A Profitable Biotech With A Potentially Undervalued Pipeline
12:24PM  United Therapeutics lower after FDA denies Remodulin citizen petition at theflyonthewall.com
12:24PM  United Therapeutics lower after FDA denies Remodulin citizen petition
28-Feb-14 01:04PM  UNITED THERAPEUTICS CORP Financials EDGAR Online Financials
27-Feb-14 08:10AM  United Therapeutics Slips on Q4 Earnings Report Zacks
08:10AM  United Therapeutics Slips on Q4 Earnings Report
26-Feb-14 09:26AM  Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls Zacks
09:26AM  Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls
25-Feb-14 06:18PM  Jazz Sings Blues On Q4 Sales, Earnings Investor's Business Daily
03:15PM  United Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
03:15PM  United Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript
12:17PM  United Therapeutics Q4 Revenue Misses, Stock Slides Optionetics
12:17PM  United Therapeutics Q4 Revenue Misses, Stock Slides at Investor's Business Daily
12:17PM  United Therapeutics Q4 Revenue Misses, Stock Slides
08:55AM  United Therapeutics Corporation Discusses Q4 2013 Results (Webcast) at Seeking Alpha
08:55AM  United Therapeutics Corporation Discusses Q4 2013 Results (Webcast)
07:07AM  Q4 2013 United Therapeutics Earnings Release - Before Market Open CCBN
06:11AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
06:10AM  UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report EDGAR Online
06:00AM  United Therapeutics Corporation Reports 2013 Fourth Quarter And Annual Financial Results PR Newswire
21-Feb-14 05:38AM  Cempra (CEMP) Jumps: Stock Adds 6.1% in Session Zacks
20-Feb-14 08:44AM  3 Biotech Stocks to Bet on this Earnings Season Zacks
18-Feb-14 06:00AM  United Therapeutics Corporation To Announce Fourth Quarter And Annual 2013 Financial Results Before Market Open On Tuesday, February 25, 2014 PR Newswire
31-Jan-14 05:11PM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure EDGAR Online
05:11PM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure
11:48AM  [video] Pluristem CEO Seeing the Future in 3D Cells at TheStreet
11:48AM  [video] Pluristem CEO Seeing the Future in 3D Cells
28-Jan-14 04:50PM  Manufacturing Approval for Pluristem Facility Zacks
04:50PM  Manufacturing Approval for Pluristem Facility
10-Jan-14 06:52PM  Cramer's homework uncovers intriguing stock at CNBC
09-Jan-14 01:00PM  Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation on Behalf of its Shareholders - UTHR PR Newswire
01:00PM  Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation on Behalf of its Shareholders - UTHR
08-Jan-14 02:10PM  Chelsea's Northera Gets Another Chance at Motley Fool
02:10PM  Chelsea's Northera Gets Another Chance
07-Jan-14 11:20AM  Pluristem to Release Trial Results Zacks
11:20AM  Pluristem to Release Trial Results
03-Jan-14 12:34PM  Pluristem Touches 52-Week High Zacks
12:34PM  Pluristem Touches 52-Week High
06:51AM  The Zacks Analyst Blog Highlights: United Therapeutics, TESARO, Supernus, BioSpecifics Technologies and Medicines Co. Zacks
06:51AM  The Zacks Analyst Blog Highlights: United Therapeutics, TESARO, Supernus, BioSpecifics Technologies and Medicines Co.
02-Jan-14 09:48AM  Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles Zacks
09:48AM  Biotech Stock Roundup: Christmas Gift for UTHR, TSRO Tumbles
01-Jan-14 11:23AM  What You Need to Know About PAH Drugs in 2014 at Motley Fool
11:23AM  What You Need to Know About PAH Drugs in 2014
10:26AM  Biggest Winners in Health Care Last Week at Motley Fool
10:26AM  Biggest Winners in Health Care Last Week
30-Dec-13 10:30AM  Insider Trading Alert - SPLK, UTHR, IBKR, CMLS And SPG Traded By Insiders at TheStreet
28-Dec-13 12:52PM  This Week in Biotech at Motley Fool
12:52PM  This Week in Biotech
08:04AM  3 Humongous Health-Care Stocks This Week at Motley Fool
08:04AM  3 Humongous Health-Care Stocks This Week
27-Dec-13 04:40PM  United Therapeutics Surges After FDA Approval Zacks
26-Dec-13 10:30AM  Insider Trading Alert - WDC, ODP, TRLA, KLIC And UTHR Traded By Insiders at TheStreet
09:42AM  Why You Should Watch Ariad and Supernus Today at Motley Fool
25-Dec-13 05:22AM  United Therapeutics: 5 Different Insiders Have Sold Shares This Month at Seeking Alpha
24-Dec-13 05:16PM  Why Idenix Pharmaceuticals, Supernus Pharmaceuticals, and Westmoreland Coal Are Today's 3 Best Stocks at Motley Fool
01:21PM  On The Fly: Closing Wrap at theflyonthewall.com
10:30AM  Insider Trading Alert - ARE, LPS, UTHR, GCO And GWRE Traded By Insiders at TheStreet
10:23AM  Supernus rises on Orenitram approval AP
10:19AM  On The Fly: Early Wrap at theflyonthewall.com
09:14AM  Stocks to Watch: Supernus, Noah Education, CalAmp at The Wall Street Journal
09:06AM  On The Fly: Pre-market Movers at theflyonthewall.com
09:06AM  Why You Need To Watch Johnson & Johnson, Synergy, Sagent, and Supernus This Morning at Motley Fool
23-Dec-13 06:06PM  CalAmp drops, ImmunoCellular rises after hours at MarketWatch +30.36%
05:16PM  Why United Therapeutics, Xyratex, and Meritor Are Today's 3 Best Stocks at Motley Fool
05:09PM  Supernus Announces FDA Approval of Its Partner's Product, Orenitram(TM) GlobeNewswire
02:58PM  This Drug Company CEO Just Named Her New Drug After Herself at Forbes
02:12PM  United Therapeutics upgraded by Ladenburg Thalmann Briefing.com
02:03PM  United Therapeutics upgraded to Buy from Neutral at Ladenburg at theflyonthewall.com
02:00PM  Why United Therapeutics Corporation Shares Soared at Motley Fool
12:35PM  Midday Movers: Apple, Target, Micron & More at CNBC
11:32AM  United Therapeutics Hits High After FDA Approval at Investor's Business Daily
11:06AM  United Therapeutics rises on new drug approval AP
10:23AM  United Therapeutics: No One Saw It Coming at Barrons.com
09:10AM  United Therapeutics Shares Gain on FDA Hypertension Approval at Bloomberg
08:30AM  Morning Movers: Tiffany Drops on $450 Million Damages Award; Darden Restaurants Gains on Activist Stake at Barrons.com
07:56AM  Story Stocks from Briefing.com Briefing.com
07:28AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
05:07AM  United Therapeutics price target raised to $120 from $100 at H.C. Wainwright theflyonthewall.com
22-Dec-13 09:31PM  Did One Of The Top 10 Upside Surprises In The History Of The Biotech Sector Just Happen? at Forbes
20-Dec-13 08:21PM  United Therapeutics Wins U.S. Approval for Lung Therapy at Bloomberg
08:01PM  FDA Approves Orenitram (treprostinil) Extended-Release Tablets for the Treatment of Pulmonary Arterial Hypertension PR Newswire
19-Dec-13 12:01PM  Insider Trading Alert - CTSH, SNPS, IP, CYBX And UTHR Traded By Insiders at TheStreet
11-Dec-13 02:17PM  United Therapeutics price target raised to $110 from $85 at Argus theflyonthewall.com
09-Dec-13 05:18PM  United Therapeutics Gets Whammed by a Subpoena at Motley Fool
12:39PM  United Therapeutics gets subpoena over 3 drugs AP
06:34AM  United Therapeutics receives subpoena for 3 drugs Reuters
06:03AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
06:00AM  United Therapeutics Receives Subpoena From Office of Inspector General PR Newswire
25-Nov-13 03:01PM  Can United Therapeutics Survive Against New Competitors? at Motley Fool
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of TransCon Treprostinil and TransCon Beraprost for the treatment of PAH; glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JEFFS ROGERPresident & COOApr 15Option Exercise27.9710,000279,70011,234Apr 15 04:06 PM
JEFFS ROGERPresident & COOApr 15Sale95.0610,000950,6301,234Apr 15 04:06 PM
ROTHBLATT MARTINE ACEOApr 10Option Exercise32.369,066293,3835,373Apr 10 05:50 PM
ROTHBLATT MARTINE ACEOApr 10Sale96.189,066871,993140Apr 10 05:50 PM
JEFFS ROGERPresident & COOApr 08Option Exercise27.9710,000279,70011,234Apr 09 04:12 PM
JEFFS ROGERPresident & COOApr 08Sale95.0010,000950,0001,234Apr 09 04:12 PM
JEFFS ROGERPresident & COOApr 04Option Exercise30.7510,000307,50011,234Apr 07 04:04 PM
JEFFS ROGERPresident & COOApr 04Sale93.2210,000932,2491,234Apr 07 04:04 PM
DWEK RAYMONDDirectorApr 03Option Exercise30.753,00092,2503,000Apr 07 04:02 PM
CAUSEY CHRISTOPHERDirectorApr 03Option Exercise31.171,50046,7552,233Apr 07 04:01 PM
MAHON PAUL AEVP & General CounselApr 03Option Exercise30.756,000184,50040,832Apr 07 04:05 PM
ROTHBLATT MARTINE ACEOApr 03Option Exercise32.369,066293,3835,373Apr 07 04:06 PM
Ferrari John MaximCFOApr 03Option Exercise47.5010,000475,00010,407Apr 07 04:06 PM
DWEK RAYMONDDirectorApr 03Sale95.843,000287,5200Apr 07 04:02 PM
CAUSEY CHRISTOPHERDirectorApr 03Sale95.671,500143,504733Apr 07 04:01 PM
MAHON PAUL AEVP & General CounselApr 03Sale93.106,000558,60034,832Apr 07 04:05 PM
ROTHBLATT MARTINE ACEOApr 03Sale93.749,066849,827140Apr 07 04:06 PM
Ferrari John MaximCFOApr 03Sale93.2210,000932,200407Apr 07 04:06 PM
JEFFS ROGERPresident & COOApr 01Option Exercise27.9710,000279,70011,234Apr 01 06:20 PM
JEFFS ROGERPresident & COOApr 01Sale95.4410,000954,3551,234Apr 01 06:20 PM
ROTHBLATT MARTINE ACEOMar 27Option Exercise32.369,066293,3835,373Mar 27 08:41 PM
ROTHBLATT MARTINE ACEOMar 27Sale93.359,066846,275140Mar 27 08:41 PM
JEFFS ROGERPresident & COOMar 25Option Exercise27.9710,000279,70011,234Mar 26 04:50 PM
JEFFS ROGERPresident & COOMar 25Sale95.6410,000956,3751,234Mar 26 04:50 PM
JEFFS ROGERPresident & COOMar 21Option Exercise30.7510,000307,50011,234Mar 21 04:16 PM
JEFFS ROGERPresident & COOMar 21Sale93.8410,000938,4491,234Mar 21 04:16 PM
MAHON PAUL AEVP & General CounselMar 20Option Exercise30.756,000184,50040,832Mar 20 06:07 PM
ROTHBLATT MARTINE ACEOMar 20Option Exercise32.369,065293,3525,372Mar 20 06:25 PM
Ferrari John MaximCFOMar 20Option Exercise47.5010,000475,00010,407Mar 21 04:15 PM
MAHON PAUL AEVP & General CounselMar 20Sale96.816,000580,86034,832Mar 20 06:07 PM
ROTHBLATT MARTINE ACEOMar 20Sale96.769,065877,097140Mar 20 06:25 PM
Ferrari John MaximCFOMar 20Sale96.1110,000961,100407Mar 21 04:15 PM
JEFFS ROGERPresident & COOMar 18Option Exercise27.9710,000279,70011,234Mar 18 04:35 PM
JEFFS ROGERPresident & COOMar 18Sale96.5110,000965,1001,234Mar 18 04:35 PM
ROTHBLATT MARTINE ACEOMar 13Option Exercise34.563,833132,4683,973Mar 13 05:06 PM
ROTHBLATT MARTINE ACEOMar 13Sale95.643,833366,587140Mar 13 05:06 PM
JEFFS ROGERPresident & COOMar 07Option Exercise30.7510,000307,50011,234Mar 07 05:14 PM
JEFFS ROGERPresident & COOMar 07Sale99.0210,000990,1701,234Mar 07 05:14 PM
Ferrari John MaximCFOMar 06Option Exercise47.5010,000475,00010,407Mar 07 05:15 PM
MAHON PAUL AEVP & General CounselMar 06Option Exercise30.756,000184,50040,832Mar 07 05:17 PM
ROTHBLATT MARTINE ACEOMar 06Option Exercise34.563,833132,4683,973Mar 06 04:21 PM
PATUSKY CHRISTOPHERDirectorMar 06Option Exercise31.175,000155,8505,000Mar 06 04:25 PM
DWEK RAYMONDDirectorMar 06Option Exercise30.753,00092,2503,000Mar 06 04:29 PM
MAHON PAUL AEVP & General CounselMar 06Sale101.936,000611,57334,832Mar 07 05:17 PM
Ferrari John MaximCFOMar 06Sale99.0710,000990,700407Mar 07 05:15 PM
ROTHBLATT MARTINE ACEOMar 06Sale102.773,833393,919140Mar 06 04:21 PM
PATUSKY CHRISTOPHERDirectorMar 06Sale101.395,000506,9500Mar 06 04:25 PM
DWEK RAYMONDDirectorMar 06Sale101.393,000304,1700Mar 06 04:29 PM
KURZWEIL RAYDirectorFeb 28Option Exercise48.1115,000721,65015,000Feb 28 05:47 PM
KURZWEIL RAYDirectorFeb 28Sale101.4215,0001,521,3000Feb 28 05:47 PM
ROTHBLATT MARTINE ACEOFeb 27Option Exercise34.563,833132,4683,973Feb 27 05:41 PM
ROTHBLATT MARTINE ACEOFeb 27Sale100.683,833385,893140Feb 27 05:41 PM
JEFFS ROGERPresident & COOFeb 21Option Exercise30.7510,000307,50010,897Feb 21 07:22 PM
JEFFS ROGERPresident & COOFeb 21Sale104.8910,0001,048,941897Feb 21 07:22 PM
ROTHBLATT MARTINE ACEOFeb 20Option Exercise34.563,833132,4683,973Feb 21 07:20 PM
MAHON PAUL AEVP & General CounselFeb 20Option Exercise30.756,000184,50040,490Feb 21 07:21 PM
ROTHBLATT MARTINE ACEOFeb 20Sale103.913,833398,274140Feb 21 07:20 PM
MAHON PAUL AEVP & General CounselFeb 20Sale104.636,000627,77134,490Feb 21 07:21 PM
ROTHBLATT MARTINE ACEOFeb 13Option Exercise34.563,833132,4683,973Feb 13 04:36 PM
ROTHBLATT MARTINE ACEOFeb 13Sale99.873,833382,809140Feb 13 04:36 PM
JEFFS ROGERPresident & COOFeb 07Option Exercise30.7510,000307,50010,897Feb 07 05:11 PM
JEFFS ROGERPresident & COOFeb 07Sale96.6110,000966,100897Feb 07 05:11 PM
MAHON PAUL AEVP & General CounselFeb 06Option Exercise30.756,000184,50040,490Feb 06 08:20 PM
DWEK RAYMONDDirectorFeb 06Option Exercise30.753,00092,2503,000Feb 06 08:25 PM
CAUSEY CHRISTOPHERDirectorFeb 06Option Exercise31.171,50046,7552,233Feb 06 08:31 PM
ROTHBLATT MARTINE ACEOFeb 06Option Exercise34.563,833132,4683,973Feb 06 08:37 PM
MAHON PAUL AEVP & General CounselFeb 06Sale97.416,000584,48234,490Feb 06 08:20 PM
DWEK RAYMONDDirectorFeb 06Sale97.333,000292,0010Feb 06 08:25 PM
CAUSEY CHRISTOPHERDirectorFeb 06Sale97.351,500146,028733Feb 06 08:31 PM
ROTHBLATT MARTINE ACEOFeb 06Sale97.263,833372,809140Feb 06 08:37 PM
ROTHBLATT MARTINE ACEOJan 30Option Exercise34.563,833132,4683,973Jan 30 07:07 PM
ROTHBLATT MARTINE ACEOJan 30Sale106.253,833407,258140Jan 30 07:07 PM
ROTHBLATT MARTINE ACEOJan 23Option Exercise34.563,833132,4683,973Jan 24 05:00 PM
ROTHBLATT MARTINE ACEOJan 23Sale111.783,833428,445140Jan 24 05:00 PM
JEFFS ROGERPresident & COOJan 17Option Exercise30.7510,000307,50010,897Jan 21 04:36 PM
JEFFS ROGERPresident & COOJan 17Sale113.0310,0001,130,250897Jan 21 04:36 PM
ROTHBLATT MARTINE ACEOJan 16Option Exercise34.563,833132,4683,973Jan 16 06:56 PM
MAHON PAUL AEVP & General CounselJan 16Option Exercise30.756,000184,50040,490Jan 16 07:06 PM
MAHON PAUL AEVP & General CounselJan 16Sale111.986,000671,90734,490Jan 16 07:06 PM
ROTHBLATT MARTINE ACEOJan 16Sale111.213,833426,287140Jan 16 06:56 PM
ROTHBLATT MARTINE ACEOJan 09Option Exercise34.563,833132,4683,973Jan 09 04:08 PM
PATUSKY CHRISTOPHERDirectorJan 09Option Exercise31.175,000155,8505,000Jan 09 04:09 PM
ROTHBLATT MARTINE ACEOJan 09Sale108.353,833415,314140Jan 09 04:08 PM
PATUSKY CHRISTOPHERDirectorJan 09Sale110.005,000550,0000Jan 09 04:09 PM
DWEK RAYMONDDirectorJan 02Option Exercise30.753,00092,2503,000Jan 03 05:07 PM
CAUSEY CHRISTOPHERDirectorJan 02Option Exercise31.171,50046,7552,233Jan 03 05:08 PM
ROTHBLATT MARTINE ACEOJan 02Option Exercise34.563,833132,4683,973Jan 03 05:07 PM
DWEK RAYMONDDirectorJan 02Sale111.413,000334,2180Jan 03 05:07 PM
CAUSEY CHRISTOPHERDirectorJan 02Sale111.411,500167,111733Jan 03 05:08 PM
ROTHBLATT MARTINE ACEOJan 02Sale111.543,833427,549140Jan 03 05:07 PM
ROTHBLATT MARTINE ACEODec 31Sale112.6418,1402,043,214533,094Dec 31 08:48 PM
ROTHBLATT MARTINE ACEODec 30Sale111.6018,1472,025,266551,234Dec 31 07:52 AM
ROTHBLATT MARTINE ACEODec 27Sale113.1518,1472,053,410569,381Dec 27 07:31 PM
ROTHBLATT MARTINE ACEODec 26Option Exercise34.563,833132,4683,973Dec 26 07:06 PM
ROTHBLATT MARTINE ACEODec 26Sale111.593,833427,723140Dec 26 07:06 PM
ROTHBLATT MARTINE ACEODec 26Sale112.0318,1482,033,120587,528Dec 26 07:06 PM
ROTHBLATT MARTINE ACEODec 24Sale114.0518,1492,069,943605,676Dec 24 04:14 PM
ROTHBLATT MARTINE ACEODec 23Sale109.481,847202,208628,486Dec 23 08:59 PM
ROTHBLATT MARTINE ACEODec 23Sale109.715,743630,041630,333Dec 23 08:54 PM
ROTHBLATT MARTINE ACEODec 23Sale110.235,898650,123636,076Dec 23 08:27 PM